Navigation Links
Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results
Date:3/27/2009

CORAL GABLES, Fla., March 27 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, today reported financial results for the fourth quarter and year ended December 31, 2008.

"Catalyst made significant progress in 2008," said Patrick J. McEnany, Chief Executive Officer of Catalyst Pharmaceutical Partners. "During the year, we initiated two U.S. multi-center, Phase II, double-blind, placebo-controlled trials evaluating CPP-109 as a potential treatment for cocaine and methamphetamine addiction. In September we executed a successful equity financing for $4.5 million just prior to the deterioration of the capital markets and the economy. This equity raise, combined with the recently announced change in our clinical development program, provides Catalyst with sufficient working capital through 2010. Furthermore, once we report initial top-line results for our U.S. Phase II cocaine trial, our strengthened balance sheet should allow us to engage potential corporate partners and explore a variety of transactions on terms that may prove to be more favorable to our shareholders. Concurrently, we are actively pursuing government funding from agencies that operate under the National Institutes of Health umbrella to further our development plans for large-scale clinical trials using CPP-109 to treat cocaine and methamphetamine addiction, as well as pilot studies for other addictions, such as alcohol and nicotine abuse, and obsessive-compulsive disorders, including binge eating."

Financial Results

For the year ended December 31, 2008, the Company's net loss was $10,564,597, or $0.81 per basic and diluted share, compared to a net loss of $4,139,493, or $0.
'/>"/>

SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Using catalysts to stamp nanopatterns without ink
2. Experiments reveal unexpected activity of fuel cell catalysts
3. UCT Specialties (Formerly Petrarch) Announces the Release of Their New Product Guides for Silanes, Silicones, Platinum Catalyst and Glass Coatings
4. IDEXX Laboratories Announces First Customer Deliveries of Catalyst Dx(TM) Chemistry Analyzer and SNAPshot Dx(TM) Analyzer
5. Catalyst Pharmaceutical Partners, Inc. Files Form S-3 Shelf Registration Statement
6. Controlling the size of nanoclusters: First step in making new catalysts
7. Catalyst Pharmaceutical Partners Reports Second Quarter 2008 Financial Results
8. NIST and partners identify tiny gold clusters as top-notch catalysts
9. Catalyst Pharmaceutical Partners, Inc. Announces a $4.5 Million Registered Direct Common Stock Offering
10. Catalyst Pharmaceutical Partners to Present at the Rodman & Renshaw 10th Annual Global Investment Conference
11. PointCross Releases Catalyst for Building Business-Ready SharePoint Solutions in 1/10th the Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... NEW YORK , May 21, 2015  Prima ... biotechnology company that is striving to become a leader ... of cancer, recently announced that the final CVac data ... has shown a clear trend for a clinically meaningful ... ("SOC") in second remission patients. In the ...
(Date:5/21/2015)... , May 21, 2015 Imagine ... feelings - and those of others. Being able to ... Analyze and read people to anticipate their thoughts and ... deepest emotions and feelings to create unique abstract paintings ... responsive games. Get inside a first-person-shooter as it creates ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... - RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: ... on the development of autologous cell therapies, announced ... Society for Cellular Therapy (ISCT) on RepliCel,s autologous ... a Phase 1/2 clinical trial.  The presentation, taking ... PM to 7:00 PM local time, will review ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 25 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3
... launched its revolutionary Trusted LASIK S,urgeons directory service ... to provide a resource for consumers seeking to ... Surgeons directory apart is a unique screening process ... best in LASIK Eye Surgery, Laser Surgeons in ...
... first and only FDA-approved once-daily amoxicillin, in the first quarter of 2009 ... MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK ), today announced it has ... , , ... president, sales & business development. Koos brings nearly 20 years, experience ...
... DIEGO, Nov. 19 Kornberg Associates Architects,( http://www.kornberg.com ) ... been,retained by the Okinawa Institute for Science and Technology ... campus and graduate,university. Ken Kornberg, president and founder, made ... "Having a presence in Japan opens up many doors ...
Cached Biology Technology:Trusted LASIK Surgeons Welcomes LASIK Expert Michael Raizman of Boston to its Unique LASIK Directory 2Trusted LASIK Surgeons Welcomes LASIK Expert Michael Raizman of Boston to its Unique LASIK Directory 3Trusted LASIK Surgeons Welcomes LASIK Expert Michael Raizman of Boston to its Unique LASIK Directory 4Trusted LASIK Surgeons Welcomes LASIK Expert Michael Raizman of Boston to its Unique LASIK Directory 5Trusted LASIK Surgeons Welcomes LASIK Expert Michael Raizman of Boston to its Unique LASIK Directory 6MiddleBrook Pharmaceuticals Hires Key Commercial Team Members 2MiddleBrook Pharmaceuticals Hires Key Commercial Team Members 3MiddleBrook Pharmaceuticals Hires Key Commercial Team Members 4MiddleBrook Pharmaceuticals Hires Key Commercial Team Members 5Kornberg Associates Architects Opens Tokyo Office 2
(Date:4/6/2015)... OXFORD, Conn. , Apr. 6, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... it has filed provisional patent 62/143028 for ... CLOSE-PROXIMITY COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces ... wireless payments. This patent surrounds the use of ...
(Date:4/2/2015)... -- At its 2015 ACMG Annual Clinical Genetics Meeting ... American College of Medical Genetics and Genomics (ACMG) announced ... Members of the ACMG Board of Directors serve as ... its policies and programs. ACMG is the national organization ... eventful time in medical genetics and genomics.  We are ...
(Date:4/2/2015)... Sweden , April 2, 2015 ... its touch fingerprint sensor FPC1025 from the distributor World ... will commence during Q2 2015 although the major part ... The sensors will be used by smartphone manufacturers in ... 110 MSEK is included in the communicated revenue guidance ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... Oregon Health & Science University (OHSU) and Legacy Health ... useable in standard diabetes pumps. Such a formulation could ... in people with type 1 diabetes (T1D) who are ... to future-generation artificial pancreas systems that dispense more than ...
... stagnated for over twenty years. That is the main conclusion ... University of Groningen into this type of prosthesis, which is ... Development . High operating force , The ... and the University of Groningen, measured the force required to ...
... news in one setting might spell disaster in another. In ... grow and divide without restraint, it,s a welcome message for ... harbors this cell in his or her body. Weizmann Institute ... molecular message that prompts unbridled cellular growth. The molecular ...
Cached Biology News:Liquid glucagon formulation discovered for potential use in artificial pancreas systems 2Development of prosthetic hands stagnated for 20 years 2Kill the messenger 2
For demonstration of Helicobacter pylori...
... with SR-101 Labeled Substrates (red fluorescence; ... measure serine protease activation • No ... FLISP Kits utilize cell-permeable, fluorescently labeled ... measure chymotrypsin-like activity in whole living ...
... mitochondrial transmembrane potential is one ... that occur following induction of ... Kit utilizes a lipophilic cation, ... mitochondrial activity marker. MitoLight partitions ...
... MitoPT kit is used in conjunction with your ... and induce apoptosis according to your existing procedure ... a negative control). Once you have induced apoptosis ... to each population and incubate the cells for ...
Biology Products: